Document Type


Publication Date


Journal / Book Title

ACS medicinal chemistry letters


Lymphatic filariasis infects over 120 million people worldwide and can lead to significant disfigurement and disease. Resistance is emerging with current treatments, and these therapies have dose limiting adverse events; consequently new targets are needed. One approach to achieve this goal is inhibition of parasitic protein kinases involved in circumventing host defense mechanisms. This report describes structure-activity relationships leading to the identification of a potent, orally bioavailable stress activated protein kinase inhibitor that may be used to investigate this hypothesis.



Published Citation

Tummalapalli, S. R., Bhat, R., Chojnowski, A., Prorok, M., Kreiss, T., Goldberg, R., ... & Rotella, D. P. (2018). Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis. ACS medicinal chemistry letters, 9(3), 210-214.